Reviewer's report
Title:Autoimmune Pancreatitis - A Comparative Description Highlighting North
American Experiences In Diagnosis And Management
Version: 1Date:17 December 2012
Reviewer: Myung-Hwan Kim
Reviewer's report:
1. The authors performed a study to review presentation and outcomes of
patients with AIP, and to report the applicability of diagnostic criteria in Canadian
patients.
First of all, there is no new discovery about AIP patients except they are
Canadian patients. Regarding AIP patients in North America, many studies have
already been published from Mayo, MGH, Pittsburgh, and so on. A simple report
of clinical features from one center may contribute minimally to current
knowledge. There are already many studies from a variety of nations, and even
international multicenter study exists (Pancreas 2011;46:809).
2. Regarding applicability of diagnostic criteria, it was already reported from
North American population by Pittsburgh group (Am J Gastroenterogy
2009;104:2295). Moreover, revised HISORt criteria (2009) and international
consensus criteria for AIP (2011) were already published. In this study, the
authors only used HISORt (2006), Japan Pancreas Society (2006), Korean
(2007) Criteria.
3. I’m not sure that all patients included for this study are really AIP because their
proportion of positive response to steroid therapy is too low, when compared with
reported response rate (>95%). Especially, their patient with PSC and elevated
IgG4 (Table 3) should be differentiated from IgG4-related sclerosing cholangitis.
Only elevation of serum IgG4 cannot diagnose IgG4-related sclerosing
cholangitis (Gastroenterology 2008;134:706).
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
Reviewer's report
Title:Autoimmune Pancreatitis - A Comparative Description Highlighting North
American Experiences In Diagnosis And Management
Version: 1Date:17 December 2012
Reviewer: Myung-Hwan Kim
Reviewer's report:
1. The authors performed a study to review presentation and outcomes of
patients with AIP, and to report the applicability of diagnostic criteria in Canadian
patients.
First of all, there is no new discovery about AIP patients except they are
Canadian patients. Regarding AIP patients in North America, many studies have
already been published from Mayo, MGH, Pittsburgh, and so on. A simple report
of clinical features from one center may contribute minimally to current
knowledge. There are already many studies from a variety of nations, and even
international multicenter study exists (Pancreas 2011;46:809).
2. Regarding applicability of diagnostic criteria, it was already reported from
North American population by Pittsburgh group (Am J Gastroenterogy
2009;104:2295). Moreover, revised HISORt criteria (2009) and international
consensus criteria for AIP (2011) were already published. In this study, the
authors only used HISORt (2006), Japan Pancreas Society (2006), Korean
(2007) Criteria.
3. I’m not sure that all patients included for this study are really AIP because their
proportion of positive response to steroid therapy is too low, when compared with
reported response rate (>95%). Especially, their patient with PSC and elevated
IgG4 (Table 3) should be differentiated from IgG4-related sclerosing cholangitis.
Only elevation of serum IgG4 cannot diagnose IgG4-related sclerosing
cholangitis (Gastroenterology 2008;134:706).
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Autoimmune Pancreatitis - A Comparative Description Highlighting North
American Experiences In Diagnosis And Management
Version: 1Date:17 December 2012
Reviewer: Myung-Hwan Kim
Reviewer's report:
1. The authors performed a study to review presentation and outcomes of
patients with AIP, and to report the applicability of diagnostic criteria in Canadian
patients.
First of all, there is no new discovery about AIP patients except they are
Canadian patients. Regarding AIP patients in North America, many studies have
already been published from Mayo, MGH, Pittsburgh, and so on. A simple report
of clinical features from one center may contribute minimally to current
knowledge. There are already many studies from a variety of nations, and even
international multicenter study exists (Pancreas 2011;46:809).
2. Regarding applicability of diagnostic criteria, it was already reported from
North American population by Pittsburgh group (Am J Gastroenterogy
2009;104:2295). Moreover, revised HISORt criteria (2009) and international
consensus criteria for AIP (2011) were already published. In this study, the
authors only used HISORt (2006), Japan Pancreas Society (2006), Korean
(2007) Criteria.
3. I’m not sure that all patients included for this study are really AIP because their
proportion of positive response to steroid therapy is too low, when compared with
reported response rate (>95%). Especially, their patient with PSC and elevated
IgG4 (Table 3) should be differentiated from IgG4-related sclerosing cholangitis.
Only elevation of serum IgG4 cannot diagnose IgG4-related sclerosing
cholangitis (Gastroenterology 2008;134:706).
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
assistant